Abingdon Health (LSE:ABDX), the lateral flow diagnostics specialist quoted on London's AIM market, has issued a notice of results, signalling that its full-year figures for the financial year ended 30 June 2026 are due shortly. The announcement follows a trading update earlier in the summer in which the company reported Revenue growth of 31% for the year and said it had reached adjusted EBITDA profitability in the second half. More recently, the company marked the official opening of its Manufacturing hub in the United States.
What the Company Does
Abingdon Health develops and manufactures rapid diagnostic tests, particularly lateral flow tests, which give quick results from samples such as blood, saliva or urine. Much of its Business involves providing contract development and manufacturing services to other organisations that want to bring their own tests to market, covering everything from early development through regulatory support to large-scale production. The company also markets some tests under its own brands. Its customers range from healthcare and life sciences businesses to organisations in animal health and other sectors.
Latest Developments
The opening of the US manufacturing hub is a significant step in the company's international strategy. Abingdon had earlier announced an expansion of its US manufacturing site, and the official opening gives it a production presence closer to American customers. The company has also issued an update on its Partnership with 4TEEN4 Pharmaceuticals, a German biotechnology business, although details of the update were not available at the time of writing. Abingdon secured a 2.5 million dollar contract for clinical self-test development, illustrating the kind of contract services work that underpins its revenue. The award's date was not confirmed.
Financial Picture
The 31% revenue increase reported in the full-year trading update, together with the move to adjusted EBITDA profitability in the second half, suggests the business has been gaining operational Leverage as volumes rise. Earlier in the year, the company published a trading update for the six months to 31 December 2025, followed by interim results and an investor presentation. Precise revenue totals, cash balances and statutory profit or loss figures were not available at the time of writing, and these are likely to be clarified in the forthcoming full-year results. The company does not currently appear to pay a dividend.
Sector and index Context
Abingdon Health sits within the healthcare segment of the FTSE AIM All Share Index. The diagnostics sector saw a boom in Demand for lateral flow tests during the Covid-19 pandemic, followed by a sharp fall as that demand faded, forcing many companies to rebuild around broader testing markets. Growth in self-testing, home health monitoring and decentralised diagnostics is widely seen as a long-term opportunity, while contract manufacturers can benefit from customers outsourcing production rather than building their own facilities.
Key Risks
Key risks include the timing and size of contract awards, which can make revenue uneven, and dependence on customers successfully commercialising their products. Expanding manufacturing in the US involves execution risk and upfront costs. Regulatory requirements for diagnostic products are demanding and can delay launches. Competition from other contract manufacturers and diagnostic companies is another factor, and smaller AIM shares can be volatile.
What to Watch Next
The main near-term event is the publication of full-year results for the year to 30 June 2026, which should provide detailed figures behind the revenue growth and second-half profitability. Investors are also likely to watch for progress at the US manufacturing hub, new contract wins, developments in the 4TEEN4 partnership and any outlook comments for the current financial year.



_11_18_2026_06_43_20_247880.jpg)


Please wait processing your request...